Sankyo Co., Ltd. revised consolidated earnings guidance for year ending March 31, 2023. For the period, the company expected net sales of JPY 135,000 million against JPY 110,000 million as Previous forecast, Operating income of JPY 45,000 million against JPY 29,000 million as Previous forecast, Profit attributable to owners of parent of JPY 35,000 million against JPY 20,000 million as Previous forecast, Net income per share of JPY 602.71 against JPY 344.40 as Previous forecast.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,633 JPY | -1.98% | -0.79% | -0.71% |
10:20am | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.71% | 2.36B | |
-25.78% | 718M | |
+12.18% | 695M | |
+31.17% | 367M | |
+0.71% | 342M | |
+4.63% | 340M | |
-8.40% | 262M | |
+16.30% | 188M | |
+27.77% | 101M | |
-28.61% | 62.86M |
- Stock Market
- Equities
- 6417 Stock
- News Sankyo Co., Ltd.
- Sankyo Co., Ltd. Revises Consolidated Earnings Guidance for Year Ending March 31, 2023